Redeye comments on Raketech’s Q3-results which were weaker than expected, driven mainly by Sub-affil...
Redeye returns with an update following Alzecure's Q3 report.
I dag offentliggjorde Angler Gaming sin delårsrapport för Kv3 2024.
Redeye comments on Thunderful Group’s Q3’24 report, which was weaker than expected, primarily due to...
Redeye provides its initial take on Surgical Science’s Q3 2024 report, which beat our expectations.
Redeye updates its view on Lifecare following its Q3 report.
Stigande affärsaktivitet Bolaget rapporterade en minskning av nettoomsättningen under det tredje kva...
Redeye comments on Better Collective’s Q3-results which were in line with the preliminary announceme...
Redeye somewhat cuts its forecasts and Base Case following a Q3 with soft ARR growth yet lower OPEX ...
Solid outlook remains for an acceleration in Q4 Limited sales and adj.
Nettoomsättningen uppgick till 204,8 MSEK (193,3), vilket motsvarade en ökning med 6,0 procent y-o-y...
AcuCort (”AcuCort” eller ”Bolaget”) meddelade den 13 november år 2024 att samtliga patienter har gen...
Redeye is favourable to InfraCom’s Q3 2024 report, which resulted in the stock rallying 9%, although...
Q3 in line with pre-announcement Strong Q4 on the cards; 20% sales growth q-o-q No change to FY guid...
Redeye comments on Gentoo Media’s Q3-results which were in line with the preliminary results announc...
Redeye sees a Q3 report from BrightBid on the soft side regarding ARR growth.
Redeye has updated its estimates and valuation following Physitrack’s Q3 report.
Redeye saw a Q3 report in which sales and gross margins slightly exceeded our estimates.
Redeye updates on EG7 post Q3-results which were better than expected, driven by strong profitabilit...
Higher sales and gross margin in Q3 EBIT revised up 12.
